Immunisation Against Hepatitis B in BMT- and Leukemia-Patients

Rosendahl, Carla; Bender-Götze, Ch.; Deinhardt, Friedrich; Kolb, Hans‐Jochem; Haas, Richard

doi:10.1007/978-3-662-40457-7_83

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,6 Attempts at active immunization against HBV in the immediate pre-and post-BMT period were unsuccessful, probably due to inefficient T cell-dependent B cell responses, which may last for about a year following BMT. 10,11 Failure of effective immunization in BMT recipients was also reported for other vaccines, such as Pseudomonas, rubella, mumps, and measles. 10,12 Over the last 10 years, adoptive transfer of humoral and cell-mediated immunity to BMT recipients through vaccination of bone marrow donors has been suggested as a means of protecting immunocompromised patients against bacterial and viral infections.…”

mentioning

confidence: 90%

Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients

Ilan

Nagler

Zeira

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Adoptive transfer of immunity against hepatitis B surface antigen (HBsAg) has been documented in mice and humans. In the present study, we report long-term follow-up of antibodies to HBsAg in humans who received allogeneic bone marrow transplantation (BMT) from donors immunized with HBsAg. BM donors were immunized with recombinant HBsAg. BM or PB cells were transplanted to HLA matched recipients. Recipients were followed for anti-HBs seroconversion. Control groups included non-immunized or rHBsAg immunized healthy adults as well as individuals that had had hepatitis B and recovered spontaneously. PBLs were stimulated in vitro with rHBsAg and stimulation was expressed as stimulation index. Adoptive transfer of immunity to HBsAg was initially documented in 12 recipients of BM from anti-HBc+/anti-HBs+ donors. An almost 4 year follow-up showed detectable protective anti-HBs levels (Ͼ10 mIU/ml) in 50% of patients. Immunity to HBV was also documented in 22/35 BMT recipients (62%), who received their bone marrow from actively immunized donors. In 7/9 of these BMT recipients, anti-HBs antibodies levels were documented 25 months following BMT. In 6/8 (75%) of patients who received only PBLs from HBV immune donors, adoptive transfer of immunity to HBV, and seroconversion to HBsAg+, were documented within 2 months of i.v. injection. Evidence for specific cellular immune response with increased SIs was documented for healthy vaccinees, and BMT recipients, and in none of the healthy non-vaccinated controls. These results suggest that adoptive transfer of immunity to HBV is a useful method for providing long-lasting protection for BM recipients. Bone Marrow Transplantation (2000) 26, 633-638.

show abstract

mentioning

confidence: 90%

Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients

Ilan

Nagler

Zeira

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The enhancement of anti-HBV immunity in HBsAg negative recipients is important as anti-HBs positivity has been shown to confer protection against HBV after receiving HBsAg positive marrow (5,8,9). The use of this prophylactic anti-HBV therapy decreased the frequency of HBV-related hepatitis in HBsAg negative recipients from 45.5% to 0%.…”

Section: Discussionmentioning

confidence: 99%

“…Despite the intensive myeloablation and immuno-suppressive effects of allogeneic HSCT, the protective effect of anti-HBV immunity seems to be preserved in some of the hepatitis B surface antibody (anti-HBs) positive recipients (5,9). The persistence of anti-HBV activity in these recipients after transplantation may be due to residual recipient lymphocytes that have survived the intensive preconditioning regime.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Prophylactic Anti-HBV Therapy in Allogeneic Hematopoietic Stem Cell Transplantation with HBsAg Positive Donors

Hui

Lie

et al. 2005

American Journal of Transplantation

View full text Add to dashboard Cite

“…[3]. Active immunization against HBV in the pre-and immediate post-BMT period was found to be ineffective, probably due to the absence of T cell-dependent B cell responses, which lasts for approximately I year following BMT [5].…”

Section: Introductionmentioning

confidence: 99%

Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors

Ilan

Nagler

Shouval

et al. 1994

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYBone marrow transplantation (BMT) recipients are immunosuppressed and are at risk for contracting severe infections. Recently, adoptive transfer of immunity against hepatitis B virus (HBV) was documented in BMT recipients receiving bone marrow from 'naturally* HBV-infected individuals who recovered spontaneously, or those transplanted with bone marrow cells obtained from actively immunized donors. Furthermore, reconstitution of the immune system in a BMT recipient who was a hepatitis surface antigen (HBsAg)*/HBV DNA' carrier with HBV immune bone marrow ceils led to clearance of the replicating virus, presumably through adoptive cellmediated immunotherapy. We report three cases of induction of immunity to HBV by selective adoptive transfer by i.v. injection of peripheral blood lymphocytes (PBL) obtained from BMT donors who were actively immunized against HBV after harvesting of bone marrow. Ail three BMT recipients developed anti-HBs antibodies. In one BMT case in whom antibodies to HBsAg developed tbllowing adoptive transfer of immune PBL, a mild booster effect was documented in the BMT recipient upon immunization with a recombinant hepatitis B vaccine. The two remaining patients lost their antibodies to HBsAg in association with relapse of leukaemia. This immune manipulation may open the door to evaluation of adoptive transfer of immunity to HBV through selective transplantation of HBV immune lymphocytes in selected patients such as those with persistent HBV infection, as well as liver transplant recipients who require protection of the graft against HBV re-infection.

show abstract

Immunisation Against Hepatitis B in BMT- and Leukemia-Patients

Cited by 5 publications

References 0 publications

Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients

Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients

Effectiveness of Prophylactic Anti-HBV Therapy in Allogeneic Hematopoietic Stem Cell Transplantation with HBsAg Positive Donors

Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors

Contact Info

Product

Resources

About